3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Advanced Solid Tumor
13
Leukemia, Myeloid, Acute
10
Carcinoma, Non-Small-Cell Lung
7
Advanced Solid Tumors
7
Breast Neoplasms
6
Solid Tumor
5
Pancreatic Neoplasms
5
Melanoma
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Solid Tumors
3
Recurrence
3
Myelodysplastic Syndromes
3
Lung Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Advanced Malignant Solid Tumor
3
Advanced Lung Cancer
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
pembrolizumab
12
Cisplatin
5
Cetuximab
5
Paclitaxel
4
durvalumab
3
Nivolumab
3
Ipilimumab
3
Gemcitabine
3
Cyclophosphamide
3
poly ICLC
2
avelumab
2
Radiation
2
Pemetrexed
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vistusertib
1
tislelizumab
1
tirbanibulin
1
spartalizumab
1
sonidegib
1
sitravatinib
1
repotrectinib
1
pralsetinib
1
pertuzumab
1
pepinemab
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma
×
Injections
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled